Technical Analysis for NTLA - Intellia Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Reached Overbought | Strength | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| Weak + Overbought | Other | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| 20 DMA Support | Bullish | -1.00% | |
| Pocket Pivot | Bullish Swing Setup | -1.00% | |
| Up 3 Days in a Row | Strength | -1.00% | |
| Up 4 Days in a Row | Strength | -1.00% | |
| Gapped Down | Weakness | -1.00% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 18 hours ago |
| Down 2 % | about 22 hours ago |
| Down 1% | about 23 hours ago |
| Rose Above Previous Day's High | about 23 hours ago |
| Up 2% | about 23 hours ago |
Get a Trading Sidekick!
- Earnings date: 02/22/2023
Intellia Therapeutics, Inc. Description
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Immune System Emerging Technologies Molecular Biology Genetics Precision Medicine Hepatitis B Metabolism Hematopoietic Stem Cell Liver Disease Amyloid Amyloidosis Chimeric Antigen Receptor T Cell Chimeric Antigen Receptor Hepatitis B Virus Antitrypsin Deficiency CRISPR Genome Editing Cell Product Inborn Errors Of Metabolism Cas9 Transthyretin Transthyretin Amyloidosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 104.78 |
| 52 Week Low | 32.435 |
| Average Volume | 1,228,193 |
| 200-Day Moving Average | 51.63 |
| 50-Day Moving Average | 40.51 |
| 20-Day Moving Average | 36.71 |
| 10-Day Moving Average | 36.82 |
| Average True Range | 2.39 |
| RSI | 52.61 |
| ADX | 14.37 |
| +DI | 27.71 |
| -DI | 20.73 |
| Chandelier Exit (Long, 3 ATRs) | 32.95 |
| Chandelier Exit (Short, 3 ATRs) | 39.59 |
| Upper Bollinger Bands | 40.47 |
| Lower Bollinger Band | 32.95 |
| Percent B (%b) | 0.76 |
| BandWidth | 20.48 |
| MACD Line | -0.62 |
| MACD Signal Line | -1.20 |
| MACD Histogram | 0.5807 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 41.78 | ||||
| Resistance 3 (R3) | 41.92 | 41.02 | 41.26 | ||
| Resistance 2 (R2) | 41.02 | 40.21 | 40.95 | 41.08 | |
| Resistance 1 (R1) | 39.82 | 39.72 | 39.37 | 39.68 | 40.90 |
| Pivot Point | 38.92 | 38.92 | 38.69 | 38.85 | 38.92 |
| Support 1 (S1) | 37.72 | 38.11 | 37.27 | 37.58 | 36.36 |
| Support 2 (S2) | 36.82 | 37.62 | 36.75 | 36.18 | |
| Support 3 (S3) | 35.62 | 36.82 | 36.01 | ||
| Support 4 (S4) | 35.48 |
